Citations

Showing 10 of 108083 citations.

Assessment of procoagulant potential in patients with reactive thrombocytosis and its association with platelet count
Rottenstreich, Amihai , Shai, Ela , Kleinstern, Geffen , Spectre, Galia, Varon, David, Kalish, Yosef

Mayo Clinic

European Journal of Haematology | December 14, 2017 | Volume: 100 | Issue: 3 | Pages: 286-293

10.1111/ejh.13012 | PMID 29240268 Get It

AbstractObjectiveWe aimed to determine hemostatic changes and characterize the procoagulant potential among patients with reactive thrombocytosis (RT).MethodsSixty patients with RT (median platelet count 718 × 109/L) and 20 healthy persons were tested for complete blood count, C‐reactive protein, von Willebrand factor (VWF), factor VIII and fibrinogen, and thrombin generation. Platelet studies, including light transmission aggregometry and Cone and Plate(let) Analyzer, were also conducted. Reticulated platelets and platelet P‐selectin expression were measured using flow cytometry.ResultsCompared to patients with mild thrombocytosis (platelet count 500‐700 × 109/L; n = 27), those with moderate‐to‐severe thrombocytosis (platelet count >700 × 109/L; n = 33) had significantly higher fibrinogen, factor VIII, and VWF antigen and activity levels; higher endogenous thrombin potential, peak thrombin generation and velocity index levels, and shorter time‐to‐peak thrombin level. VWF antigen and activity, fibrinogen, and factor VIII were positively associated with platelet count, whereas VWF activity/antigen ratio was inversely correlated. In a multivariate analysis of RT and control participants, only platelet count predicted endogenous thrombin potential with a positive‐linear correlation. No patients developed acquired von Willebrand syndrome.ConclusionsAs determined by thrombin generation, RT was associated with in vitro prothrombotic tendency, which correlated with platelet count. This may explain the increased thromboembolic risk previously reported in patients with RT.
The Epidemiology and Clinical Associations of Portal Vein Thrombosis in Hospitalized Patients With Cirrhosis: A Nationwide Analysis From the National Inpatient Sample
Shah, Shawn L. , Shatzel, Joseph J. , Toor, Arifa , Dickson, Rolland C. , Anderson, Joseph C.

Mayo Clinic

Journal of Hospital Medicine | December 14, 2017 | Volume: 13 | Issue: 5 | Pages: 324-325

10.12788/jhm.2888 | PMID 29240852 Get It

Comparison of infliximab with adalimumab in 827 biologic‐naïve patients with Crohn's disease: a population‐based Danish cohort study
Singh, Siddharth , Loftus, Edward V. , Jess, Tine , Singh, S , Jess, T , Loftus, Edward V , Andersen, Nynne Nyboe , Andersson, Mikael

Mayo Clinic

Alimentary Pharmacology & Therapeutics | December 14, 2017 | Volume: 47 | Issue: 5 | Pages: 596-604

10.1111/apt.14466 | PMID 29239001 Get It

SummaryBackgroundThere are conflicting data on comparative effectiveness of adalimumab and infliximab in patients with Crohn's disease (CD).AimsTo compare the effectiveness and safety of adalimumab and infliximab in biologic‐naïve patients with CD, in a nationwide register‐based propensity score‐matched cohort study in Denmark.MethodsA total of 2908 Danish adults with CD had been treated with adalimumab or infliximab as their first biologic agent between 2005‐2014. By Cox regression, we compared rates of all‐cause hospitalisation, CD‐related hospitalisation, major abdominal surgery and serious infections after variable 2:1 propensity score matching, accounting for baseline disease characteristics, healthcare utilisation and use of CD‐related medications.ResultsAfter propensity‐score matching, we included 315 adalimumab‐ (34.9 ± 12.9 years, 41.9% males) and 512 infliximab‐treated (33.6 ± 12.6 years, 40.8% males) patients, with median disease duration 4.0 years; 36.9% had prior abdominal surgery. Over a median follow‐up 2.3 years after starting biological therapy, there were no significant differences in rate of CD‐related hospitalisation (hazard ratio [HR], 0.81 [95% CI, 0.55‐1.20]) or major abdominal surgery (HR, 1.24 [0.66‐2.33]) between adalimumab‐ and infliximab‐treated patients, though rate of all‐cause hospitalisation was lower in adalimumab‐treated patients (HR, 0.74 [0.56‐0.97]). There was no significant difference in incidence of serious infections requiring hospitalisation (HR, 1.06 [0.26‐4.21]). These results were stable in patients treated with biological monotherapy (all‐cause hospitalisation: HR, 0.75 [0.53‐1.05]; CD‐related hospitalisation: HR, 0.82 [0.51‐1.32], abdominal surgery: HR, 1.47 [0.63‐3.47]) or in combination with immunomodulators (all‐cause hospitalisation: HR, 0.70 [0.44‐1.11]; CD‐related hospitalisation: HR, 0.80 [0.42‐1.52], abdominal surgery: HR, 1.02 [0.39‐2.64]).ConclusionsIn this population‐based, propensity score matched, real‐life cohort study using administrative claims, there was no significant difference in effectiveness and safety of adalimumab and infliximab in biologic‐naïve patients with CD.
Challenges in surgical pathology of adrenocortical tumours
Erickson, Lori A. , Erickson, Lori A

Mayo Clinic

Histopathology | December 14, 2017 | Volume: 72 | Issue: 1 | Pages: 82-96

10.1111/his.13255 | PMID 29239032 Get It

Adrenocortical carcinomas are rare tumours that can be diagnostically challenging. Numerous multiparametric scoring systems and diagnostic algorithms have been proposed to differentiate adrenocortical adenoma from adrenocortical carcinoma. Adrenocortical neoplasms must also be differentiated from other primary adrenal tumours, such as phaeochromocytoma and unusual primary adrenal tumours, as well as metastases to the adrenal gland. Myxoid, oncocytic and sarcomatoid variants of adrenocortical tumours must be recognized so that they are not confused with other tumours. The diagnostic criteria for oncocytic adrenocortical carcinoma are different from those for conventional adrenocortical carcinomas. Adrenocortical neoplasms in children are particularly challenging to diagnose, as histological features of malignancy in adrenocortical neoplasms in adults may not be associated with aggressive disease in the tumours of children. Recent histological and immunohistochemical studies and more comprehensive and integrated genomic characterizations continue to advance our understanding of the tumorigenesis of these aggressive neoplasms, and may provide additional diagnostic and prognostic utility and guide the development of therapeutic targets.
Autologous CD34+ cell therapy improves exercise capacity, angina frequency and reduces mortality in no-option refractory angina: a patient-level pooled analysis of randomized double-blinded trials
Henry, Timothy D. , Losordo, Douglas W. , Schatz, Richard A. , Jolicoeur, E Marc, Schaer, Gary L. , Clare, Robert M., White, Christopher J. , Fortuin, F. David , Kereiakes, Dean J. , Zeiher, Andreas M. , Sherman, Warren, Hunt, Andrea S, Povsic, Thomas J. , Traverse, Jay H. , Jolicoeur, E Marc, Chiswell, Karen

Mayo Clinic

European Heart Journal | December 14, 2017 | Volume: 39 | Issue: 23 | Pages: 2208-2216

10.1093/eurheartj/ehx764 | PMID 29315376 Get It

Concordance between administrative data and clinical review for mortality in the randomized on/off bypass follow-up study (ROOBY-FS)
Quin, Jacquelyn A. , Hattler, Brack , Kemp, Darlene, Almassi, G. Hossein , Bakaeen, Faisal G. , Carr, Brendan M. , Bishawi, Muath , Collins, Joseph F. , Grover, Frederick L., Wagner, Todd H. , Shroyer, A. Laurie

Mayo Clinic

Journal of Cardiac Surgery | December 13, 2017 | Volume: 32 | Issue: 12 | Pages: 751-756

10.1111/jocs.13379 | PMID 29239024 Get It

The pain of terror
Mack, Kenneth J. , Heyer, Geoffrey L.

Mayo Clinic

Neurology | December 13, 2017 | Volume: 90 | Issue: 2 | Pages: 53-54

10.1212/wnl.0000000000004813 | PMID 29237793 Get It

Recommendations of the Global Multiple System Atrophy Research Roadmap Meeting
Walsh, Ryan R., Krismer, Florian , Galpern, Wendy R., Wenning, Gregor K. , Low, Phillip A. , Halliday, Glenda M. , Holton, Janice L. , Quinn, Niall , Rascol, Olivier , Shaw, Leslie M. , Eidelberg, David , Bower, Pam, Abler, Victor, Biedenharn, Judy, Bitan, Gal , Brundin, Patrik , Fernandez, Hubert, Fortier, Philip, Gasser, Thomas , Hewitt, Alice, Höglinger, Günter U. , Huentelman, Matt , Jensen, Poul Henning , Jeromin, Andreas, Kang, Un Jung , Kaufmann, Horacio , Kellerman, Lawrence R., Khurana, Vikram , Klockgether, Thomas , Kim, Woojin S. , Langer, Carol B., Masliah, Eliezer , Meissner, Wassilios G. , Ostrowitzki, Susanne, Piantadosi, Steven , Roemer, Cyndi, Schenk, Dale, Schlossmacher, Michael G. , Seppi, Klaus , Shih, Lily, Siderowf, Andrew , Stebbins, Glenn T. , Stefanova, Nadia , Sutton, Sharon Egretta, Zhang, Jing , Halliday, Glenda , Koroshetz, Walter J. , Holton, Janice, Quinn, Niall P, Brooks, David J. , Hewitt, Art, Huentelman, Matt J, Jensen, Poul H, Kellerman, Lawrence, Kim, Woojin Scott, Langer, Carol, LeWitt, Peter, Meissner, Wassilios, Melki, Ronald, Poewe, Werner, Schlossmacher, Michael, Schmahmann, Jeremy D, Tsuji, Shoji , Sutton, Sharon, Kaufmann, Horacio , Meissner, Wassilios G , Höglinger, Günter U , Krismer, Florian , Seppi, Klaus , Cummings, Jeffrey L. , Fortier, P, Freeman, Roy L. , LeWitt, Peter A. , Melki, Ronald , Poewe, Werner H , Robertson, David L. , Schmahmann, Jeremy Dan , Sutton, Sharon

Mayo Clinic

Neurology | December 13, 2017 | Volume: 90 | Issue: 2 | Pages: 74-82

10.1212/wnl.0000000000004798 | PMID 29237794 Get It

Likelihood of pulmonary hypertension in patients with idiopathic pulmonary fibrosis and emphysema
Jacob, Joseph , Bartholmai, Brian J. , Rajagopalan, Srinivasan , Karwoski, Ronald A., Nair, Arjun , Walsh, Simon, Barnett, Joseph , Cross, Gary , Judge, Eoin P., Kokosi, Maria , Renzoni, Elisabetta , Maher, Toby M. , Wells, Athol U. , Karwoski, Ronald, Bartholmai, Brian J , Maher, Toby

Mayo Clinic

Respirology | December 13, 2017 | Volume: 23 | Issue: 6 | Pages: 593-599

10.1111/resp.13231 | PMID 29237236 Get It

ABSTRACT Background and objective This study evaluated whether patients with combined pulmonary fibrosis and emphysema (CPFE) have an increased likelihood of pulmonary hypertension (PHT) when compared with idiopathic pulmonary fibrosis (IPF) patients without emphysema. Methods Two consecutive IPF populations having undergone transthoracic echocardiography were examined ( n = 223 and n = 162). Emphysema and interstitial lung disease (ILD) extent were quantified visually; ILD extent was also quantified by a software tool, CALIPER. Echocardiographic criteria categorized PHT risk. Results The prevalence of an increased PHT likelihood was 29% and 31% in each CPFE cohort. Survival at 12 months was 60% across both CPFE cohorts with no significantly worsened outcome identified when compared with IPF patients without emphysema. Using logistic regression models in both cohorts, total computed tomography (CT) disease extent (ILD and emphysema) predicted the likelihood of PHT. After adjustment for total disease extent, CPFE had no stronger association with PHT likelihood than IPF patients without emphysema. Conclusion Our findings indicate that the reported association between CPFE and PHT is explained by the summed baseline CT extents of ILD and emphysema. Once baseline severity is taken into account, CPFE is not selectively associated with a malignant microvascular phenotype, when compared with IPF patients without emphysema.
Point-Counterpoint: Piperacillin-Tazobactam Should Be Used To Treat Infections with Extended-Spectrum-Beta-Lactamase-Positive Organisms
Reyes, Sergio , Schuetz, Audrey N. , Tamma, Pranita D.

Mayo Clinic

Journal of Clinical Microbiology | December 13, 2017 | Volume: 56 | Issue: 3 | Pages: No page available

10.1128/jcm.01917-17 | PMID 29237787 Get It

INTRODUCTIONBeta-lactam/beta-lactamase inhibitor combination antimicrobials (BLBLIs) are among the most controversial classes of antibiotic agents available for the treatment of infections caused by extended-spectrum-beta-lactamase (ESBL)-producing Gram-negative bacteria (ESBL-GNR). Piperacillin-tazobactam (PTZ) is one of the most frequently utilized antibiotic agents for empirical Gram-negative bacterial coverage and remains active against a large proportion of ESBL-GNR strains. Furthermore, good antimicrobial stewardship practices encourage the use of carbapenem-sparing treatment regimens for infections due to ESBL-GNR. As rapid diagnostics are increasingly used in the clinical microbiology laboratory and have the capability of detecting CTX-M type or other ESBL resistance mechanisms, this issue continues to be pertinent. Some data imply reduced efficacy of PTZ against ESBLs. Several factors may affect a clinician's choice to use BLBLIs, including the isolate's MIC, the site and severity of infection, and the type of resistance mechanism. These factors are explored in this review of the pros and cons of BLBLI treatment of invasive infections due to ESBL-producing bacteria, as well as how laboratories should report results for BLBLIs for these organisms as they relate to antimicrobial stewardship. In this Point-Counterpoint, Audrey Schuetz provides the pro point of view and Sergio Reyes and Pranita Tamma provide the con, counterpoint view.